Antibiotics for Periodontal Infections: Biological and Clinical Perspectives

Mahuli, Simpy Amit; Zorair, Ali M; Jafer, Mohammed; Sultan, Alnomari; Sarode, Gargi S; Baeshen, Hosam Ali; Raj, A. Thirumal; Sarode, Sachin C.; Patil, Shankargouda

doi:10.5005/jp-journals-10024-2797

Cited by 19 publications

(11 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic and local pharmacological drugs can help in reducing the disease progression. The most commonly used drugs are antibiotics, such as tetracyclines, in non-antimicrobial doses to inhibit collagenolytic activities and activities of neutrophils and osteoclasts [ 16 , 17 ]. The anti-inflammatory drugs most commonly used are NSAIDs (non-steroidal anti-inflammatory drugs) which block the cyclooxygenase pathway of arachidonic acid metabolism [ 18 ].…”

Section: Host Modulationmentioning

confidence: 99%

Future Drug Targets in Periodontal Personalised Medicine—A Narrative Review

Yadalam

Varatharajan

Fageeh

et al. 2022

JPM

View full text Add to dashboard Cite

Periodontal disease is an infection-driven inflammatory disease characterized by the destruction of tooth-supporting tissues. The establishment of chronic inflammation will result in progressive destruction of bone and soft tissue changes. Severe periodontitis can lead to tooth loss. The disease has complex pathogenesis with an interplay between genetic, environmental, and host factors and pathogens. Effective management consists of plaque control and non-surgical interventions, along with adjuvant strategies to control inflammation and disrupt the pathogenic subgingival biofilms. Recent studies have examined novel approaches for managing periodontal diseases such as modulating microbial signaling mechanisms, tissue engineering, and molecular targeting of host inflammatory substances. Mounting evidence suggests the need to integrate omics-based approaches with traditional therapy to address the disease. This article discusses the various evolving and future drug targets, including proteomics, gene therapeutics, vaccines, and nanotechnology in personalized periodontal medicine for the effective management of periodontal diseases.

show abstract

Section: Host Modulationmentioning

confidence: 99%

Future Drug Targets in Periodontal Personalised Medicine—A Narrative Review

Yadalam

Varatharajan

Fageeh

et al. 2022

JPM

View full text Add to dashboard Cite

show abstract

“…An excessive immune response to bacteria is responsible for periodontal tissue destruction [ 2 ]. Currently, antibiotics administered locally to periodontal lesions are used for treatment, but the problem of resistant bacteria has been pointed out [ 3 ], and new anti-inflammatory substances are expected to be discovered.…”

Section: Introductionmentioning

confidence: 99%

6-(Methylsulfinyl) Hexyl Isothiocyanate Inhibits IL-6 and CXCL10 Production in TNF-α-Stimulated Human Oral Epithelial Cells

Shimoyama

Hosokawa

et al. 2022

CIMB

View full text Add to dashboard Cite

6-(Methylsulfinyl) hexyl isothiocyanate (6-MSITC) is a bioactive substance found in wasabi (Wasabia japonica) and has been reported to have some bioactive effects including anticancer and antioxidant effects. However, there are no reports on its effects on periodontal resident cells, and many points remain unclear. In this study, we aimed to investigate whether 6-MSITC exerts anti-inflammatory effects on human oral epithelial cells, including effects on signal transduction pathway activation. 6-MSITC inhibited interleukin (IL)-6 and C-X-C motif chemokine ligand 10 (CXCL10) production in TNF-α-stimulated TR146 cells, which are a human oral epithelial cell line. Moreover, we found that 6-MSITC could suppress signal transducer and activator of transcription (STAT)3, nuclear factor (NF)-κB, and p70S6 kinase (p70S6K)-S6 ribosomal protein (S6) pathways activation in TNF-α-stimulated TR146 cells. Furthermore, STAT3 and NF-κB inhibitors could suppress IL-6 and CXCL10 production in TNF-α-treated TR146 cells. In summary, 6-MSITC could decrease IL-6 and CXCL10 production in human oral epithelial cell by inhibiting STAT3 and NF-κB activation.

show abstract

“…At the moment, periodontal lesions are treated with antibiotics that are supplied locally in the conventional treatment of periodontal disease. Since the problem of resistant bacteria has been raised [ 3 ], new anti-inflammatory compounds are expected to be identified.…”

Section: Introductionmentioning

confidence: 99%

The Anti-Inflammatory Effects of Iberin on TNF-α-Stimulated Human Oral Epithelial Cells: In Vitro Research

Hosokawa

Shimoyama

et al. 2022

Biomedicines

View full text Add to dashboard Cite

Iberin is a bioactive chemical found in cruciferous plants that has been demonstrated to have anticancer properties. However, there have been no reports on its effects on periodontal resident cells, and many questions remain unanswered. The aim of this study was to examine whether iberin had anti-inflammatory effects on human oral epithelial cells, including influences on signal transduction pathway activation in TNF-α-στιμυλατεd χελλσ. Iberin inhibited the production of interleukin (IL)-6 and C-X-C motif chemokine ligand 10 (CXCL10), as well as the expression of vascular cell adhesion molecule (VCAM)-1, inducible nitric oxide synthase (iNOS), and cyclooxygenase (COX)-2 in tumor necrosis factor (TNF)-α-stimulated TR146 cells, a human oral epithelial cell line. Moreover, iberin administration increased the expression of antioxidant signaling pathways, such as Heme Oxygenase (HO)-1 and NAD(P)H quinone dehydrogenase 1 (NQO1). Furthermore, we found that iberin could inhibit the activation of the nuclear factor (NF)-κB, signal transducer and activator of transcription (STAT)3, and p70S6 kinase (p70S6K)-S6 ribosomal protein (S6) pathways in TNF-α-stimulated TR146 cells. In conclusion, iberin reduced inflammatory mediator expression in human oral epithelial cells by preventing the activation of particular signal transduction pathways.

show abstract

Antibiotics for Periodontal Infections: Biological and Clinical Perspectives

Cited by 19 publications

References 52 publications

Future Drug Targets in Periodontal Personalised Medicine—A Narrative Review

Future Drug Targets in Periodontal Personalised Medicine—A Narrative Review

6-(Methylsulfinyl) Hexyl Isothiocyanate Inhibits IL-6 and CXCL10 Production in TNF-α-Stimulated Human Oral Epithelial Cells

The Anti-Inflammatory Effects of Iberin on TNF-α-Stimulated Human Oral Epithelial Cells: In Vitro Research

Contact Info

Product

Resources

About